key: cord-0733026-s2ka4rj0
authors: Valencia, Guillermo Arturo; Neciosup, Silvia; Gómez, Henry L; Benites, Maria Del Pilar; Falcón, Silvia; Moron, David; Veliz, Karin; Maldonado, Mike; Auqui, Rodrigo
title: Adaptation of international coronavirus disease 2019 and breast cancer guidelines to local context
date: 2021-01-24
journal: World J Clin Oncol
DOI: 10.5306/wjco.v12.i1.31
sha: 5103ce813f9605394c0f0a578a8f6dd162a0e0ae
doc_id: 733026
cord_uid: s2ka4rj0

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (a novel coronavirus), which was first identified amid an outbreak of respiratory illness cases in Wuhan, China and declared a global health emergency, is currently considered an additional challenge in the management of patients with breast cancer (BC). Cancer patients are more vulnerable to becoming infected with severe acute respiratory syndrome coronavirus 2 and are more likely to suffer additional complications that can increase mortality. Identifying those BC patients who require more urgent therapy than others in the current situation is essential. These recommendations are based on and have been adapted from those similarly published by international scientific societies for BC management. They are divided mainly by clinical stage (early, advanced), subtype [luminal, human epidermal growth factor receptor 2 (HER2), triple-negative], or type of medical treatment and setting (neoadjuvant, adjuvant, metastatic). Recommendations for HER2 and triple-negative subtypes are similar, whereas in luminal subtype there are various options of management. The objective is to adapt guidelines to local context through relevant decision-makers, avoiding duplication of efforts and optimizing use or resources. We hope that these recommendations will help medical oncologists provide the best quality care to BC patients during the COVID-19 pandemic with information tailored to our healthcare system. AIM: To establish and adapt recommendations from those published by international scientific societies for BC management. METHODS: The Peruvian Society of Medical Oncology developed a consensus and propose here a manuscript with recommendations for oncological medical treatment of BC during the COVID-19 pandemic. The Peruvian Society of Medical Oncology invited a panel of experts and opinion leaders on BC working in major health care systems around Peru. Panel experts selected three international clinical practice guidelines (National Comprehensive Cancer Network, European Society for Medical Oncology, Spanish Foundation Research Group in Breast Cancer), considering that these are more representative in COVID-19 management. Also, the panel agreed to include at least one European and American clinical practice guideline. RESULTS: Recommendations about BC management during the COVID-19 pandemic were divided mainly by clinical stage (early, advanced), subtype (luminal, HER2, triple-negative), or type of medical treatment and setting (neoadjuvant, adjuvant, metastatic). Recommendations for HER2 and triple-negative subtypes were similar between clinical practice guidelines, whereas in luminal subtype there were various options of management. One hundred twelve recommendations were reviewed, adapted, and voted. A consensus was made in order to provide best decisions of management, avoid duplication of efforts, and optimize medical resources, considering health care system reality. These recommendations are not intended to replace clinical judgment. CONCLUSION: Most of recommendations are similar, mainly in high-risk subtypes (HER2, triple-negative). Certain societies adapt them to deal with different situations involving the best decision in the management of BC patients.

The rapid escalation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to a pandemic has required a fast mechanism of prioritization of health services globally, to identify and select correctly actions that assure the best management of the breast cancer (BC) patient. The risk of worse outcomes needs to be weighed against the risk of patients and health workers to SARS-CoV-2 infection [1, 2] .

The need for priority mechanisms is mandatory since there are more restrictions, especially in systems with impaired availability or accessibility (including limited human resources and lack of access to medicines). The prioritization is established according to clinical practice guidelines, which are based on the highest-level available evidence [3] [4] [5] .

The Peruvian Society of Medical Oncology (SPOM, Lima-Peru) developed a consensus and proposed a manuscript with recommendations for oncological medical treatment of BC during the coronavirus disease 2019 (COVID- 19) pandemic. SPOM invited a panel of experts and opinion leaders on BC working in major health care systems around Peru (nine in total). Panel experts selected three international clinical practice guidelines (National Comprehensive Cancer Network, European Society for Medical Oncology, Spanish Foundation Research Group in Breast Cancer), considering that these are more representative in the COVID-19 management. Also, the panel agreed to include at least one European and American clinical practice guideline. Previously, in an attempt to reduce debate and discuss controversial questions, panelists via teleconference had reviewed and exchanged recommendations.

By vote, panel of experts defined and adapted three levels of prioritization from European Society for Medical Oncology: High, medium and low priority; to support the best decision of care in oncological medical treatment, adapting treatment recommendations to the local context.

The consensus (Friday, June 19, 2020) was held in Lima, Peru via teleconference. A moderator chaired the panel discussion and the voting. One hundred twelve recommendations were reviewed, adapted, and voted. Panelists were asked to cast their vote using three possible answers: Yes, no, abstain. "Abstain" was used in cases of insufficient data, lack of expertise on the issue in question, or panelist's conflict of interest. A percentage greater than 70% was considered a unanimous decision. Furthermore, some additional comments were added on each topic under discussion.

During the pandemic, it is recommended to choose regimens and therapeutic sequences that are the most consistent with the current situation to reduce the risk of SARS-CoV-2 infection in patients and health workers, without compromising the prognosis of patients (Yes: 100%, No: 0%). In addition, there should be a differentiated triage for COVID-19 in all cancer centers before entrance, where patients and family members are questioned about their symptoms, history contacts, as wells as a record of body temperature for fever. In case of suspected COVID-19 infection, patients and/or companions should not have contact with other patients and/or health workers and should be managed according to protocols of each institution (Yes: 100%, No: 0%).

It is important to leave a medical register (informed consent) specifying explicitly the discussion with the patient of risk/benefits of treatments in the context of a pandemic as well as therapeutic decisions and alternatives available (Yes: 78%, No: 22%). In addition, individualizing the need for blood transfusions when strictly necessary (Yes: 100%, No: 0%) ( Table 1) .

Events that require immediate in-person visit or evaluation and/or treatment (high priority) are, for example, unstable postsurgical patients (hematoma, infection, bleeding) (Yes: 100%, No: 0%) and oncological emergencies (febrile neutropenia, uncontrolled pain, symptomatic brain metastases) (Yes: 100%, No: 0%). Other conditions to evaluate in-person are BC diagnosis during pregnancy (Yes: 100%, No: 0%) and de novo locally advanced BC with aggressive phenotypes [human epidermal growth factor receptor 2 (HER2) positive, triple-negative] (Yes: 78%, No: 22%).

De novo invasive BC (Yes: 89%, No: 11%), intercurrences on-treatment patients (new signs/symptoms, abnormal findings during the physical examination, adverse events) (Yes: 100%, No: 0%), patients on active intravenous chemotherapy (Yes: 78%, No: 22%), and clinically stable routine postsurgical patients are examples of medium priorities (Table 2) .

Recommendations about telemedicine are generally classified as medium or low priority. The majority of patients could be evaluated remotely via telemedicine (if feasible) (Yes: 100%, No: 0%). In-person visits can be converted evaluating the risks of viral transmission to patients and health workers. Examples of patients with BC who can be evaluated with telemedicine are patients completing neoadjuvant chemotherapy and waiting for surgery (Yes: 89%, No: 11%), patients eligible for radiotherapy (first visit) (Yes: 89%, No: 11%), and patients receiving oral chemotherapy or endocrine therapy + targeted therapy (Yes: 78%, No: 22%).

Low priority patients are those for whom certain treatments or interventions can be deferred until pandemic is over; for example, routine evaluation in patients who are in periodic controls (observation) or endocrine therapy (Yes: 78%, No: 22%) and survivorship follow-up (Yes: 100%, No: 0%) (Table 3) .

As a high priority, clinical diagnosis of a mass or lump in the breast (with auto examination) or another sign with high suspicion of malignancy should be immediately evaluated (Yes: 100%, No: 0%). Similarly, patient should be evaluated when there is clinical evidence of relapsed locoregional disease (Yes: 100%, No: 0%). There are urgent situations that require imaging (Yes: 100%, No: 0%). It is recommended to perform additional images upon abnormal mammogram results ( e.g., Breast Imaging Reporting and Database System score 5) or suspected BC signs/symptoms (Yes: 89%, Abst: 11%) and for patients experiencing relapsed BC (Yes: 100%, No: 0%). Pathologic evaluation (cytopathology or histopathology) for abnormal mammograms or symptoms in the breast or symptomatic metastatic relapse is considered high priority (Yes: 100%, No: 0%).

Examples of medium priority in imaging include: Performing mammograms additionally with abnormal result in asymptomatic patients (Yes: 100%, No: 0%) and monitoring of treatments with echocardiograms (every 6 mo, if feasible) in patients who require treatment based in anthracyclines or anti-HER2 agents as a regular assessment of cardiac function (Yes: 78%, No: 22%). In the case of histopathologic diagnosis, examples of medium priority are biopsies for Breast Imaging Reporting and Database System score 4 or 5 Lesions (Yes: 100%, No: 0%) and image-guided (or clinically) biopsy to determine a metastatic relapse (Yes: 100%, No: 0%).

Screening and follow-up are classically considered as low priority. It is safe to deliver these scenarios during the pandemic [6, 7] (Yes: 100%, No: 0%) ( Table 4 ).

As high priority in early BC (EBC), all subtypes should complete their regimens that have already started [8] . It is reasonable to consider shorter regimens or dosemodifications (Yes: 100%, No: 0%). Patients with clinical stage (CS) I-II (including N1) and those with intermediate/low grade, "low risk" genetic profile or classified as luminal A subtype do not benefit from neo/adjuvant chemotherapy. These patients can receive endocrine therapy alone (Yes: 100%, No: 0%) [9, 10] . Recommendations about subtype are shown in Table 5 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .

Examples of medium priority involve situations in HER2 (+) EBC and luminal patients. In BC HER2 (+), anti-HER2 therapy can be restarted after remitting SARS-CoV-2 infection, following a discussion and approval by a multidisciplinary team (Yes: 

All the recommendations in these settings are considered high priority. BC patients initiating therapy or ongoing neo/adjuvant chemotherapy and who present suspected symptoms of infection or contact history with an infected person are recommended to get tested (polymerase chain reaction) before starting or continuing it. In the case of a positive result, defer treatment until confirmation of negative result with a new test (polymerase chain reaction), which could be performed between 2-3 wk later, and with previous evaluation from the Infectious Disease Department (Yes: 67%, No: 33%). Neoadjuvant treatment according to subtypes: A multidisciplinary team (using web platforms) should evaluate patients with invasive BC for the decision to initiate neoadjuvant therapy during the pandemic (Yes: 100%, No: 0%). Neoadjuvant treatment in BC with "high risk" [triple-negative, HER2 (+), luminal B with "high risk"] is recommended (Yes: 100%, No: 0%) [21, 22] . In patients with HR (+) BC, neoadjuvant endocrine therapy allows deferring definitive surgery [23] [24] [25] (Yes: 100%, No: 0%). Recommendations about subtypes are included in Table 6 [26] . 

(1) General considerations: (a) All subtypes should complete their regimens that have already started [8] . Consider shorter regimens or dosemodifications (Yes: 100%, No: 0%); and (b) Patients with CS I-II (including N1) and those with intermediate/low grade, "low risk" genetic profile, or classified as luminal A subtype do not benefit from neo/adjuvant chemotherapy. They can receive endocrine therapy alone [9, 10] (1) In patients with active infection due to COVID-19, stopping treatment is recommended;

(2) Antihormonal therapy: Endocrine therapy (tamoxifen, AI, LHRH agonists) is safe (does not affect the immune system) and can be continued during the COVID-19 pandemic. LHRH analogs can be administered every 3 mo (although home administration of LHRH analogs is the preferred recommendation); however, fulvestrant requires intramuscular monthly application [19] ; (3) Chemotherapy: schedules can be modified to reduce admissions (every 2 or 3 wks' doses can be used instead of a weekly dose with selected agents). Consider the use of concomitant colony-stimulating factor (G-CSF), preferably pegfilgrastim for single-dose administration) [20] ; and (4) 

Similar to neoadjuvant therapy for BC, all the recommendations for adjuvant therapy are the same and considered as high priority (Yes: 100%, No: 0%). Recommendations are mentioned in Table 7 .

The goals of treatment in metastatic BC (MBC) are palliative: Improvement of quality of life and prolong survival as well as minimizing adverse effects due to therapy (Yes: 100%, No: 0%). The medical criteria demand the best decision where a delay can result in fatal outcomes (e.g., a patient with visceral crisis needs to start promptly January 24, 2021 Volume 12 Issue 1 Table 8 [27] [28] [29] [30] .

The importance to divide recommendations into priorities is a complex challenge in They should be considered according to resources available and institutional practices [27] (Yes: 100%, No: 0%); (b) iCDK 4/6 can be deferred in selected patients if there is a high chance of controlling the disease with endocrine therapy alone (e.g., de novo luminal MBC with a low burden of disease without visceral metastases) (Yes: 100%, No: 0%); and (c) Palbociclib dose reduction does not reduce efficacy (Yes: 100%, No: 0%) [28, 29] ; ( If using myelosuppressive regimens, consider G-CSF to reduce the risk of neutropenia (Yes: 89%, No: 11%); and (c2) Cases where the disease is in response with one line of chemotherapy + anti-HER2 therapy, in patients classified as "high groups for COVID-19" (e.g., > 65-70 yr and/or comorbidity (diabetes, hypertension, etc.): Consider maintaining anti-HER2 therapy as maintenance (Yes: 89%, No: 11%); (7) mTNBC: (a) Recommendations with use of chemotherapy: (a1) Use regimens less frequently and with less toxicity (e.g., use paclitaxel every 2 wk -Q2W-instead of docetaxel Q3W (Yes: 78%, No: 22%); (a2) Consider G-CSF to minimize the risk of neutropenia and reduce the use of corticosteroids (Yes: 89%, No: 11%); (a3) Prefer oral chemotherapy regimens (such as capecitabine) as an alternative to the EV route (if possible) (Yes: 100%, No: 0%); (a4) Consider less immunosuppressive regimens, with a preference for monotherapy regimens rather than combinations (Yes: 100%, No: 0%); and (b) For treatment with targeted therapies, it is recommended: (b1) Immunotherapy: Consider atezolizumab + chemotherapy in patients with PD-L1 (+) mTNBC (Yes: 100%, No: 0%); and (b2) PARP inhibitors (olaparib, talazoparib): Evaluate risk/benefit (myelotoxicity) and drug interactions (Yes: 100%, No: 0%); and (8) Second-line and subsequent lines: (a) Offer second-line, third-line, or subsequent lines of treatment when therapy can deliver clinical benefit and impact on outcomes (Yes: 100%, No: 0%); (b) In HER2 (+) MBC, after progression with trastuzumab, evaluate treatment with T-DM1 and/or other available therapies, always maintaining anti-HER2 blockade (Yes: 100%, No: 0%); (c) Some doses may be deferred to minimize risk of infection during the COVID-19 pandemic (Yes: 100%, No: 0%); and (d) In MBC, after a multidisciplinary discussion and according to the patient's preferences, terms such as "therapeutic rest", palliative therapy or maintenance regimens with dose reduction can be offered, depending on the case (Yes: 89%, No: 11%) clinical decision-making. The purpose of this guideline is to prioritize patient scenarios by the urgency of treatment and make recommendations based on these priorities without compromising outcomes. This manuscript must be interpreted and adapted according to each oncologist's necessity, prioritizing physician judgment, and is not intended to replace institutional health policies or local guidelines. The goal of this manuscript is to orient and guide health workers related to medical oncology in the development of action plans to maintain the best outcomes for BC patients in the COVID-19 era. Recommendations about "high risk" subtypes (HER2, triple-negative) were similar in guidelines. Conversely, there was certain discordance in luminal subtype, with more flexible options of oncological medical treatment in each scenario (neoadjuvant, adjuvant, early, metastatic). For example, consider the assessment of clinical criteria or genomic platforms for the final decision of therapy in early BC. Consensus was made in order to avoid discordances. The goal of this manuscript is adapting guidelines to local context through relevant decision-makers in order to avoid duplication of efforts and optimize use of medical resources according to the national system [31] .

This manuscript was adapted to a Latin America health system. For example, SPOM used some recommendations in order to generate best decisions of oncological medical treatment in Peru.

The COVID-19 pandemic represents a unique challenge for patients, clinicians, and the healthcare system. During the COVID-19 pandemic, minimization of exposure risk and preservation of resources are mandatory because there is a need of recommendations according to national realities and possibilities of health services access, without affecting the health of cancer patients. International clinical practice guidelines have formulated guidelines for the management of BC in the COVID-19 era involving all scenarios, most recommendations are similar, mainly in high-risk subtypes (HER2, triple-negative). Certain societies haven adapted these recommendations, including a panel vote with percentages, to deal with different situations involving the best decision in the management of BC patients. This manuscript has used and summarized three clinical practice guidelines, showing a broad vision (American, European) of BC management using different approaches and generating a consensus for adapting to our health system reality.

The evaluation of the reality of access to health services in our country (Peru) is mandatory in coronavirus disease 2019 (COVID-19) era as is the prioritization of different approaches to determine which patients with cancer [in this case with breast cancer (BC)] need immediate treatment or those in which treatment can be deferred until pandemic is over. BC is one of the most frequent tumors in Peru, similar to other countries of Latin America and globally.

In Peru there is no information about a consensus or local guidelines of BC and COVID-19 management.

The main objective is to adapt international clinical practice guidelines to local context through best decision-makers, avoid duplication of efforts, and optimize medical resources, since Peru has many limitations to access a optimal health care attention.

Peruvian Society of Medical Oncology invited an expert panel (including nine medical oncologists, opinion leaders in Peru) who reviewed and were asked to cast their vote. Decisions were discussed with a consensus though teleconference. One hundred twelve recommendations were reviewed, and priority categories were defined and adapted in three levels based on the severity and urgency of an individual patient's

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Available from: h ttps://cdn.www.gob.pe/uploads/document/file/694551/Manejo_te%CC%81cnico_de_pacientes_oncol o%CC%81gicos_durante_COVID-19.PDF 2 NCCN Guidelines. Recommendations for Priorization, Treatment and Triage of Breast Cancer Patients During the COVID-19 Pandemic. The COVID-19 Pandemic Breast Cancer Consortium

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast cancer

Documento GEICAM sobre el manejo del paciente con cáncer de mama en la situación de pandemia de COVID-19 en España. 2 de abril de

The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study

Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR

Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

PERSEPHONE Steering Committee and Trial Investigators. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison with Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants with Operable HER2-Positive Primary Breast Cancer

Switching taxane-trastuzumab to T-DM1 shows no benefit in KAITLIN trial

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

San Antonio Breast Cancer Symposium. GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT). Available from

Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer

Short-Term Recommendations Specific to Issues with COVID-19 (SRS-CoV-2)

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer

Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial

Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)

Abstract P5-21-21: Palbociclib exposure-response analyses in the treatment of hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC)

Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer

Adapting clinical practice guidelines to local context and assessing barriers to their use